A full-time, permanent position is available for the role of statistician at the National Centre for Pharmacoeconomics. All relevant information is available from the St James's Hospital website. Closing date for applications is Thursday 12 December 2019.
The NCPE recommends midostaurin (Rydapt®) for AML not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments. *
The NCPE recommends that venetoclax in combination with rituximab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments.*